Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBlack Diamond Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$0.42 | -$0.19 | -$0.29 |
| Q2 2025 | 2 | -$0.30 | -$0.30 | -$0.30 |
| Q3 2025 | 2 | -$0.32 | -$0.32 | -$0.32 |
| Q4 2025 | 2 | -$0.34 | -$0.34 | -$0.34 |
| Q1 2026 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q2 2026 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q3 2026 | 1 | -$0.17 | -$0.17 | -$0.17 |
| Q4 2026 | 1 | -$0.17 | -$0.17 | -$0.17 |
Black Diamond Therapeutics, Inc. Earnings Date And Information
Black Diamond Therapeutics, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-0.28 earnings per share for the quarter, topping analysts' consensus estimates of $-0.37 by $0.09. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Black Diamond Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.88 diluted earnings per share) and currently has a price-to-earnings ratio of -1.72. Black Diamond Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based on prior year's report dates.
Black Diamond Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$0.37 | -$0.28 | 0.09 | $0 | $0 |
| 08/06/2024 | Q2 2024 | -$0.39 | -$0.36 | 0.03 | $0 | $0 |
| 05/09/2024 | Q1 2024 | -$0.44 | -$0.35 | 0.09 | $0 | |
| 03/12/2024 | Q4 2023 | -$0.47 | -$0.38 | 0.09 | $4.89 M | |
| 11/06/2023 | Q3 2023 | -$0.49 | -$0.45 | 0.04 | $0 | |
| 08/11/2023 | Q2 2023 | -$0.54 | -$0.52 | 0.02 | $0 | |
| 05/09/2023 | Q1 2023 | -$0.61 | -$0.55 | 0.06 | $0 | |
| 03/09/2023 | Q4 2022 | -$0.63 | -$0.47 | 0.16 | $0 | |
| 11/08/2022 | Q3 2022 | -$0.64 | -$0.57 | 0.07 | $0 | |
| 08/09/2022 | Q2 2022 | -$0.68 | -$0.61 | 0.07 | $0 | |
| 05/11/2022 | Q1 2022 | -$0.75 | -$0.69 | 0.06 | $0 | |
| 03/17/2022 | Q4 2021 | -$1.01 | -$0.71 | 0.3 | $0 | |
| 11/08/2021 | Q3 2021 | -$0.98 | -$0.97 | 0.01 | $0 | |
| 08/12/2021 | Q2 2021 | -$0.87 | -$0.95 | -0.08 | $0 | |
| 05/07/2021 | Q1 2021 | -$0.67 | -$0.84 | -0.17 | $0 | |
| 03/25/2021 | Q4 2020 | -$0.63 | -$0.63 | 0 | $0 | |
| 11/10/2020 | Q3 2020 | -$0.53 | -$0.50 | 0.03 | $0 | |
| 08/11/2020 | Q2 2020 | -$0.43 | -$0.41 | 0.02 | $0 | |
| 05/12/2020 | Q1 2020 | -$0.47 | -$0.51 | -0.04 | $0 | |
| 03/24/2020 | Q4 2019 | -$0.30 | $0 |
Black Diamond Therapeutics, Inc. Earnings: FAQ's
When is Black Diamond Therapeutics, Inc.'s earnings date?
Black Diamond Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's report dates.
Did Black Diamond Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Black Diamond Therapeutics, Inc. (:BDTX) reported $-0.28 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.37 by $0.09.
How can I listen to Black Diamond Therapeutics, Inc.'s earnings conference
call?
The conference call for Black Diamond Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Black Diamond Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Black Diamond Therapeutics, Inc.'s latest earnings report can be read online.
How much profit does Black Diamond Therapeutics, Inc. generate each year?
Black Diamond Therapeutics, Inc. (:BDTX) has a recorded net income of $0. Black Diamond Therapeutics, Inc. has generated $-1.88 earnings per share over the last four quarters.
What is Black Diamond Therapeutics, Inc.'s price-to-earnings ratio?
Black Diamond Therapeutics, Inc. (:BDTX) has a price-to-earnings ratio of -1.72 and price/earnings-to-growth ratio is -0.16.